- Home
- NEXN vs DCTH Comparison
NEXN vs DCTH Comparison
Compare NEXN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | DCTH |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 350.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEXN | DCTH |
|---|---|---|
| Price | $5.96 | $10.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $12.00 | ★ $22.60 |
| AVG Volume (30 Days) | 390.1K | ★ 465.4K |
| Earning Date | 03-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | 0.03 |
| Revenue | ★ $376,353,000.00 | $79,603,000.00 |
| Revenue This Year | $5.43 | $131.69 |
| Revenue Next Year | N/A | $39.22 |
| P/E Ratio | ★ $9.55 | $301.98 |
| Revenue Growth | 7.80 | ★ 251.54 |
| 52 Week Low | $5.72 | $8.12 |
| 52 Week High | $12.60 | $18.23 |
Technical Indicators
Market Signals| Indicator | NEXN | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 31.44 | 56.66 |
| Support Level | $5.72 | $10.00 |
| Resistance Level | $6.90 | $10.49 |
| Average True Range (ATR) | 0.23 | 0.36 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 20.33 | 58.12 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.